Thoughts on LifeSci Capital?
Equity researcher interested in getting transaction experience with SMID biotechs and have limited insight/expectations on IB analyst programs. Any perspectives on expected experience (transaction exposure, analyst responsibilities etc.), assessment on the quality/type of IB bank, likely exits given limited history, and other points would be really helpful.
https://www.lifescicapital.com/investment-banking/
New (2018) healthcare-focused IB boutique, part of the LifeSci company network which includes the #1 U.S. biotech investor relations firm. Involved in 17 transactions in 2020 (10 follow-on offerings, 4 IPOs, 3 private placements) helping raise >$1.7B with ~$130MM average transaction size and lead manager in ~50% of the ECM transactions. Other frequent book-running managers are Jefferies, Cantor, Piper Sandler, Credit Suisse, Chardan,UBS, SVB Leerink. Also launched 2 biotech SPACs this year, raising ~$70MM and ~$80MM respectively; one of them merged with Vincera Pharma, market cap now ~$160MM.
The IB team is very lean, 4 senior leadership members and only 2 FT analysts and ~3 academic-term student analysts. ER team has 8 people. The senior leadership team has a previous senior analyst at a $2B biotech hedge fund, the previous co-head of healthcare IB at Canaccord Adams, previous healthcare M&A head at NSC, Robertson Stephens, Wells Fargo, UBS and SVP at a SMID biotech.
BUMP not asking if u have a previous perspective, just assessment based on those stats ^
Ad libero id voluptas et aliquam nihil quibusdam. Qui culpa corrupti optio est exercitationem. Vitae omnis quidem animi aut est. Iusto nobis perspiciatis non cumque. Magni voluptatem debitis consequatur et nesciunt. Et sunt hic ut est omnis. Facilis facilis ut dolorem vero ut.
See All Comments - 100% Free
WSO depends on everyone being able to pitch in when they know something. Unlock with your email and get bonus: 6 financial modeling lessons free ($199 value)
or Unlock with your social account...